Conviction
1 → 3
Conviction●●●○○3 of 5
Research target$434.42Snapshot target
Thesis statusINTACTLast reviewed 7/8/26
Market cap$25.16BSnapshot value
Research history
See all WST changes ↗What changed
Target
— → $434.42
Thesis status
NEEDS_MORE_DATA → INTACT
Last reviewed
Not reviewed → 7/8/26
Target
— → $434.42
Purest pick-and-shovel of injectables: elastomer closures + RTU components + self-injection devices. GLP-1 demand consumed high-value syringe/stopper capacity faster than suppliers can validate. Annex 1 RTU conversions additive.
GLP-1 injectable dominance (each pen bundles glass + elastomer + device); Medicare GLP-1 Bridge (live July 1 2026 ~$50 copay); ~2031 patent cliff (biosimilars still need fill-finish); SmartDose 3.5ml divestiture to AbbVie mid-2026.
Oral GLP-1 bypassing sterile bottleneck (Lilly Foundayo launched April 2026); GLP-1 ~20% exposure as swing factor; capacity coming online 2026-2027 (finite tightness); Novo/Catalent in-housing.
needs X/Reddit sentiment sweep
Snapshot · 7/8/26🟢 Lean-Bull · ins-$1.1M · 13F 17+/8- · short↓0.23
Snapshot · 7/8/26